0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

Thrombolytic Therapy and Mortality in Patients With Acute Pulmonary Embolism—Invited Commentary

Daniel J. Brotman, MD; Michael B. Streiff, MD
Arch Intern Med. 2008;168(20):2191-2192. doi:10.1001/archinte.168.20.2191.
Text Size: A A A
Published online

Extract

Systemic thrombolysis effectively and rapidly dissolves clots in the pulmonary vasculature as well as the deep veins, but unlike thrombi in coronary or cerebral arteries, a PE usually does not result in permanent tissue necrosis. Provided that the patient survives the immediate hemodynamic effects of the initial event, therapy with antithrombotics alone (heparin products followed by warfarin) will usually keep further clotting at bay, allowing the body's natural fibrinolytic system to slowly dissolve any existing thromboses. This favorable response to standard anticoagulation in the majority of patients with PE, coupled with the known hemorrhagic risks of systemic thrombolysis, limits the target population for thrombolysis to those patients at high risk for hemodynamic collapse and perhaps those at high risk for developing severe pulmonary hypertension, which occurs over the course of months to years in about 4% of patients after an index PE, particularly those with a large thrombus burden.1 The precise indications for systemic thrombolysis, however, remains uncertain and debated.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Thromboembolism or Acute Pulmonary Embolism

Users' Guides to the Medical Literature
Table 9.2-3 Refuted Evidence From Observational Studiesa

brightcove.createExperiences();